TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03975621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.
Study: NCT00754351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
Study: NCT00874445

Intervention type: DEVICE
Intervention: ICD/ CRT-D
Description: Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.

Intervention type: DEVICE
Intervention: ICD/ CRT-D
Description: Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
Study: NCT02867865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Radiotherapy will be for 5 weeks and will be given only in the study arm. The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PETCECT
Description: All the patients will undergo PETCECT to rule out metastatic disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PETCECT
Description: All the patients will undergo PETCECT to rule out metastatic disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.
Study: NCT03522051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calcium silicate based material,
Description: Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
Study: NCT04417179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominis block
Description: transversus abdominis block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block
Description: Erector spinae block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Local Anesthetic used in both blocks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Local Anesthetic used in both blocks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Acuson x300 3-5MHz Ultrasound
Description: Ultrasound used to aid in the blocks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Acuson x300 3-5MHz Ultrasound
Description: Ultrasound used to aid in the blocks
Study: NCT01226459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Minoxidil Topical Foam
Description: Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Foam
Description: Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
Study: NCT03770091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theraworx
Description: Theraworx foam applied to skin and/or compression wrap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theraworx
Description: Theraworx foam applied to skin and/or compression wrap

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo foam
Study: NCT03193762

Intervention type: OTHER
Intervention: Anxiety VAS
Description: Anxiety will be measure with a 10-points visual analogic scale (VAS)
Study: NCT00571844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet plus Weight loss
Description: Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
Study: NCT03436381

Intervention type: OTHER
Intervention: Questionaire
Description: We will provide two sleep apnea screening questionnaire, Stop-bang questionnaire and Epworth sleepiness scale
Study: NCT03366090

Intervention type: PROCEDURE
Intervention: Biopsies during coloscopy
Description: During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.

Intervention type: PROCEDURE
Intervention: Biopsies during coloscopy
Description: During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
Study: NCT00002970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT
Study: NCT03437564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablet
Study: NCT05838079

Intervention type: OTHER
Intervention: Clinical examination
Description: Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation

Intervention type: OTHER
Intervention: Clinical examination
Description: Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation

Intervention type: OTHER
Intervention: Clinical examination
Description: Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation
Study: NCT05712148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell implantation
Description: Suprachoridal mesenchymal spheroidal stem cell implantation
Study: NCT05520437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
Study: NCT01693354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mid-dilution HDF
Description: Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HF dialysis
Description: Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
Study: NCT00908024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab (Erbitux®)
Description: IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
Study: NCT03150862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Administered as specified in the treatment arm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Up to 60 Gy (total) over 6 - 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Up to 60 Gy (total) over 6 - 7 weeks
Study: NCT03150862

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Up to 60 Gy (total) over 6 - 7 weeks
Study: NCT01770470

Intervention type: DIETARY_SUPPLEMENT
Intervention: Chitosan
Description: The product chitosan is contained in a chewing gum formulation
Study: NCT04071847

Intervention type: DEVICE
Intervention: Deep Brain Stimulation (DBS)
Description: Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
Study: NCT02984579

Intervention type: DEVICE
Intervention: YD REBA MTB-MDR
Description: Conducted on stored, de-identified leftover samples. A line probe assay designed for detection of Multidrug-resistant tuberculosis (MDR-TB). The REBA MTB-MDR® assay is a qualitative in vitro test for the identification of Mycobacterium tuberculosis (MTB) complex and its susceptibility to rifampin and isoniazid from cultured samples and smear positive specimens.

Intervention type: DEVICE
Intervention: Hain Genotype MTBDRplus V1
Description: Conducted on stored, de-identified leftover samples. There is only one Line Probe Assay for molecular MTB drug resistance globally available, the GenoType® MTBDRplus V.1 from Hain Lifescience. This assay includes rpoB gene probes for Rifampin (RIF) resistance, katG gene probes for high level Isoniazid (INH) resistance, and inhA gene probes for determination of low level INH resistance

Intervention type: DEVICE
Intervention: Hain Genotype MTBDRplus V2
Description: Conducted on stored, de-identified leftover samples. An updated version of the Hain Genotype MTBDRplus V1 assay, the Genotype MTBDRplus V.2 line probe assay, showed increased sensitivity for MTB detection in the 2 studies published so far
Study: NCT04611971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benlysta
Description: Benlysta injection will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candin
Description: Candin will be administered intradermally along with NaCl solution.
Study: NCT04209036

Intervention type: OTHER
Intervention: 0° 3D laparoscopy high-definition camera(Olympus Winter & IBE GMBH, Hamburg - Germany)
Description: total laparoscopic hysterectomy using a 3D laparoscopy high-definition system
Study: NCT00927654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost (Ventavis)
Description: Twice 20 µg at day 0 (total dose 40 µg) intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride solution 0.9 % (placebo)
Description: Twice at day 0 intraoperatively
Study: NCT04660513

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Subjects with morbid obesity underwent bariatric surgery
Study: NCT03358199

Intervention type: PROCEDURE
Intervention: LOD
Description: Women underwent LOD in the preceding 3 months prior to IVF/ICSI
Study: NCT01953575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Impedance
Description: A tiny tube will be placed through the endoscope into the esophagus. 5 cm above where the stomach and esophagus meet for 5 seconds. At 10 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds. And at 20 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Impedance
Description: A tiny tube will be placed through the endoscope into the esophagus. 5 cm above where the stomach and esophagus meet for 5 seconds. At 10 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds. And at 20 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Description: Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Upper Endoscopy
Description: Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Description: Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.
Study: NCT01483716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Study: NCT02512133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIGS Hydrus Ivantis
Description: implant of the micro stent in the nasal Schlemm's canal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 360 degrees SLT
Description: Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
Study: NCT00685880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy (10% dextrose solution)
Description: Dextrose diluted with sterile water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: CELESTONE® SOLUSPAN® \* (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
Study: NCT05145998

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucola
Description: 50 grams of Glucola sugar beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole pea meal
Description: Whole cooked peas with spaghetti sauce and a slice of bread.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea flour meal
Description: Pea flour with spaghetti sauce and a slice of bread.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole lentils
Description: Whole cooked lentils with spaghetti sauce and a slice of bread.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lentil flour
Description: Lentil flour with spaghetti sauce and a slice of bread.
Study: NCT02349594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven 10%
Description: intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven 10%
Description: intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
Study: NCT03609138

Intervention type: DEVICE
Intervention: Spinal Hardware
Description: Pedicle screws and patient specific rods
Study: NCT02035085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1000 labeled SVF cells
Description: Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
Study: NCT01553188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 386
Description: AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: A 1,000 mg dose of abiraterone should be taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: A 1,000 mg dose of abiraterone should be taken orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone
Description: A 1,000 mg dose of abiraterone should be taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
Study: NCT04207801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR101
Description: Inhibitor of RORγ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR101
Description: Inhibitor of RORγ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Drug-Placebo of AUR101 tablet
Study: NCT02403570

Intervention type: OTHER
Intervention: Brain MRI